Lung memory T-cell response in mice following intranasal immunization with influenza vector expressing mycobacterial proteins

Abstract

Improving specific prevention of tuberculosis continues to be a top priority in phthisiology. “Prime-boost” vaccination schemes aim to maintain adequate levels of specific immunity while forming long-term protection. They are based on sequential use of BCG vaccine and new vaccine candidates expressing protective mycobacterial proteins. The development of new tuberculosis prevention approaches requires an understanding of how the anti-tuberculosis immune response forms and which mechanisms provide TB protection. Since tuberculosis is an airborne infection, vaccine effectiveness largely depends on mucosal immunity based on the formation of long-lived, functionally-active memory T-lymphocytes in the respiratory tract. We have previously shown that the influenza vector expressing ESAT-6 and Ag85A mycobacterial proteins (Flu/ESAT-6_Ag85A) in vaccination scheme of intranasal boost immunization resulted in significant increase of BCG's protective effect according to key indicators aggregate data in experimental tuberculosis infection. The aim of this work was to study the effect of intranasal immunization with the Flu/ESAT-6_Ag85A influenza vector on the formation of antigen-specific central and effector memory T cells and the cytokine-producing activity of effector T cells (TEM) in BCG standard and “BCG prime — influenza vector boost” vaccination schemes in mice. Intranasal immunization with the influenza vector has been shown to increase the proportion of antigen-specific CD4+ central memory T cells (TCM) in the pool of activated lymphocytes of lung and spleen reaching significant differences from the BCG group in the percentage of spleen CD4+ TCM (p < 0.01). In contrast to BCG, vaccination with the studied vaccine candidate was accompanied by accumulation of highly differentiated CD8 effector cells in lung, the target organ during tuberculosis infection. Comparative evaluation of the cell-mediated, post-vaccine immune response after immunization with influenzavector-based vaccine candidate (intranasal/mucosal) or BCG vaccine (subcutaneous) showed advantages in the mucosal group: in formation of functionally active subpopulations of effector CD4 and CD8 T lymphocytes (CD44highCD62Llow) in lungs secreting IL-2 as well as polyfunctional cells capable of coproducing two cytokines (IFNγ/TNFα or IFNγ/IL-2) or three cytokines (IFNγ/TNFα/IL-2). Due to their more pronounced effector function, polyfunctional T-lymphocytes can be considered to be potential immunological markers of protective immunity in tuberculosis.

Determining optimal conditions for growing recombinant vectors to be used in developing a bovine tuberculosis vaccine

“…on animal models, such as mice and guinea pigs, showed the vaccine to be completely safe (Buzitskaya et al, 2022). Moreover, it was established that vaccinated animals developed a strong antigen-specific T-cell immune response and a high level of protection, one that is not inferior to that offered by a commercial Bacillus Calmette-Guérin (BCG) vaccine (Shurygina et al, 2014;Stukova et al, 2014).…”

Safety and Protective Efficacy of a Candidate Vector-Based Vaccine for Bovine Tuberculosis

“…Similar studies assessing the safety of recombinant influenza viruses expressing M. tuberculosis’ proteins ESAT-6 and Ag-85 in laboratory animals such as mice and guinea pigs have proved them to be completely safe. They have also demonstrated that animals immunised with recombinant influenza viruses developed a T-cell immune response and a level of protection that was not inferior to those induced by commercial BCG vaccines [ 30 , 31 ].…”